Inhibition of EGFR Tyrosine Kinase by Erlotinib Prevents Sclerodermatous Graft-Versus-Host Disease in a Mouse Model

Journal of Investigative Dermatology

Volumn 135, Issue 10, 2015, Pages 2385-2393

  Morin, Florence ^a,b   Kavian, Niloufar ^a,b   Marut, Wioleta ^a   Chéreau, Christiane ^b   Cerles, Olivier ^b   Grange, Philippe ^a   Weill, Bernard ^a,b   Nicco, Carole ^a   Batteux, Frédéric ^a,b  

^a INSTITUT COCHIN   (France)

^b Institut Cochin   (France)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; GAMMA INTERFERON; INTERLEUKIN 13; PROTEIN TYROSINE KINASE;

ALOPECIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; B LYMPHOCYTE ACTIVATION; BONE MARROW; BONE TRANSPLANTATION; CD4+ T LYMPHOCYTE; CELL TRANSPLANTATION; CHRONIC GRAFT VERSUS HOST DISEASE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DIARRHEA; DRUG EFFECT; ENZYME INHIBITION; IMMUNOPROPHYLAXIS; LYMPHOCYTIC INFILTRATION; LYMPHOCYTOPOIESIS; MEMORY T LYMPHOCYTE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SCLERODERMA; SKIN FIBROSIS; SPLEEN CELL; VASCULITIS; ADVERSE EFFECTS; ALLOGRAFT; ANALYSIS OF VARIANCE; ANIMAL; ANTAGONISTS AND INHIBITORS; BAGG ALBINO MOUSE; DISEASE MODEL; DRUG EFFECTS; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; IMMUNOHISTOCHEMISTRY; METABOLISM; NEEDLE BIOPSY; PATHOLOGY; POLYMERASE CHAIN REACTION; PROCEDURES; RANDOMIZATION; REFERENCE VALUE; SCLERODERMA, LOCALIZED; WESTERN BLOTTING;

ALLOGRAFTS; ANALYSIS OF VARIANCE; ANIMALS; BIOPSY, NEEDLE; BLOTTING, WESTERN; CD4-POSITIVE T-LYMPHOCYTES; DISEASE MODELS, ANIMAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; ERLOTINIB HYDROCHLORIDE; FEMALE; FLOW CYTOMETRY; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; IMMUNOHISTOCHEMISTRY; INTERFERON-GAMMA; INTERLEUKIN-13; MICE; MICE, INBRED BALB C; POLYMERASE CHAIN REACTION; PROTEIN-TYROSINE KINASES; RANDOM ALLOCATION; REFERENCE VALUES; SCLERODERMA, LOCALIZED;

EID: 84941418909     PISSN: 0022202X     EISSN: 15231747     Source Type: Journal    
DOI: 10.1038/jid.2015.174     Document Type: Article

References (41)

1. Akita RW, Sliwkowski MX (2003) Preclinical studies with Erlotinib (Tarceva). Semin Oncol 30: 15-24
2. Baird K, Pavletic SZ (2006) Chronic graft versus host disease. Curr Opin Hematol 13: 426-35
3. Bruggen MC, Klein I, Greinix H et al. (2014) Diverse T-cell responses characterize the different manifestations of cutaneous graft-versus-host disease. Blood 123: 290-9
4. Chu Y-W, Gress RE (2008) Murine models of chronic graft-versus-host disease: insights and unresolved issues. Biol Blood Marrow Transplant J Am Soc Blood Marrow Transplant 14: 365-78
5. Comerford I, Harata-Lee Y, Bunting MD et al. (2013) A myriad of functions and complex regulation of the CCR7/CCL19/CCL21 chemokine axis in the adaptive immune system. Cytokine Growth Factor Rev 24: 269-83
6. Eberhard Y, Ortiz S, Ruiz Lascano A et al. (2004) Up-regulation of the chemokine CCL21 in the skin of subjects exposed to irritants. BMC Immunol 5: 7
7. Ferrara JLM, Levine JE, Reddy P et al. (2009) Graft-versus-host disease. Lancet 373: 1550-61
8. Filipovich AH, Weisdorf D, Pavletic S et al. (2005) National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant J Am Soc Blood Marrow Transplant 11: 945-56
9. Fuchs BC, Hoshida Y, Fujii T et al. (2014) Epidermal growth factor receptor inhibition attenuates liver fibrosis and development of hepatocellular carcinoma. Hepatol Baltim Md 59: 1577-90
10. Furudate S, Fujimura T, Kambayashi Y et al. (2014) Comparison of CD163+ CD206+ M2 macrophages in the lesional skin of bullous pemphigoid and pemphigus vulgaris: the possible pathogenesis of bullous pemphigoid. Dermatology 229: 369-78
11. Grange PA, Raingeaud J, Calvez V et al. (2009) Nicotinamide inhibits Propionibacterium acnes-induced IL-8 production in keratinocytes through the NF-kappaB and MAPK pathways. J Dermatol Sci 56: 106-12
12. Hamilton JD, Suárez-Fariñas M, Dhingra N et al. (2014) Dupilumab improves the molecular signature in skin of patients with moderate-to-severe atopic dermatitis. J Allergy Clin Immunol 134: 1293-300
13. Jaffee BD, Claman HN (1983) Chronic graft-versus-host disease (GVHD) as a model for scleroderma. I. Description of model systems. Cell Immunol 77: 1-12
14. Johnson JR, Cohen M, Sridhara R et al. (2005) Approval summary for erlotinib for treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of at least one prior chemotherapy regimen. Clin Cancer Res Off J Am Assoc Cancer Res 11: 6414-21
15. Kansu E (2004) The pathophysiology of chronic graft-versus-host disease. Int J Hematol 79: 209-15
16. Kavian N, Servettaz A, Mongaret C et al. (2010) Targeting ADAM-17/notch signaling abrogates the development of systemic sclerosis in a murine model. Arthritis Rheum 62: 3477-87
17. Kavian N, Marut W, Servettaz A et al. (2012) Arsenic trioxide prevents murine sclerodermatous graft-versus-host disease. J Immunol 188: 5142-9
18. Korholz D, Kunst D, Hempel L et al. (1997) Decreased interleukin 10 and increased interferon-gamma production in patients with chronic graftversus-host disease after allogeneic bone marrow transplantation. Bone Marrow Transplant 19: 691-5
19. Korngold R, Sprent J (1978) Lethal graft-versus-host disease after bone marrow transplantation across minor histocompatibility barriers in mice. Prevention by removing mature T cells from marrow. J Exp Med 148: 1687-98
20. Kumai T, Oikawa K, Aoki N et al. (2014) Tumor-derived TGF-and prostaglandin E2 attenuate anti-tumor immune responses in head and neck squamous cell carcinoma treated with EGFR inhibitor. J Transl Med 12: 265
21. Lee SJ, Klein JP, Barrett AJ et al. (2002) Severity of chronic graft-versus-host disease: association with treatment-related mortality and relapse. Blood 100: 406-14
22. Linhares YPL, Pavletic S, Gale RP (2013) Chronic GVHD: Where are we? Where do we want to be? Will immunomodulatory drugs help? Bone Marrow Transplant 48: 203-9
23. Luo Q, Gu Y, Zheng W et al. (2011) Erlotinib inhibits T-cell-mediated immune response via down-regulation of the c-Raf/ERK cascade and Akt signaling pathway. Toxicol Appl Pharmacol 251: 130-6
24. Marut W, Kavian N, Servettaz A et al. (2013) Amelioration of systemic fibrosis in mice by angiotensin II receptor blockade. Arthritis Rheum 65: 1367-77
25. Nagler A, Pines M, Abadi U et al. (2000) Oral tolerization ameliorates liver disorders associated with chronic graft versus host disease in mice. Hepatology 31: 641-8
26. Nishimori H, Maeda Y, Tanimoto M (2013) Chronic graft-versus-host disease: disease biology and novel therapeutic strategies. Acta Med Okayama 67: 1-8
27. Pastore S, Mascia F, Mariani V et al. (2008) The epidermal growth factor receptor system in skin repair and inflammation. J Invest Dermatol 128: 1365-74
28. Robert J (2011) [Tyrosine kinase inhibitors]. Bull Cancer (Paris) 98: 1321-34
29. Ruzek MC, Jha S, Ledbetter S et al. (2004) A modified model of graft-versushost-induced systemic sclerosis (scleroderma) exhibits all major aspects of the human disease. Arthritis Rheum 50: 1319-31
30. Saeki H, Tamaki K (2006) Thymus and activation regulated chemokine (TARC)/ CCL17 and skin diseases. J Dermatol Sci 43: 75-84
31. Schneider MR, Wolf E (2009) The epidermal growth factor receptor ligands at a glance. J Cell Physiol 218: 460-6
32. Servettaz A, Goulvestre C, Kavian N et al. (2009) Selective oxidation of DNA topoisomerase 1 induces systemic sclerosis in the mouse. J Immunol 182: 5855-64
33. Shlomchik WD (2007) Graft-versus-host disease. Nat Rev Immunol 7: 340-52
34. Socié G, Ritz J (2014) Current issues in chronic graft-versus-host disease. Blood 124: 374-84
35. Vogelsang GB, Lee L, Bensen-Kennedy DM (2003) Pathogenesis and treatment of graft-versus-host disease after bone marrow transplant. Annu Rev Med 54: 29-52
36. Wolff D, Gerbitz A, Ayuk F et al. (2010) Consensus conference on clinical practice in chronic graft-versus-host disease (GVHD): first-line and topical treatment of chronic GVHD. Biol Blood Marrow Transplant 16: 1611-28
37. Wolff D, Schleuning M, von Harsdorf S et al. (2011) Consensus Conference on Clinical Practice in Chronic GVHD: second-line treatment of chronic graft-versus-host disease. Biol Blood Marrow Transplant 17: 1-17
38. Yahata Y, Shirakata Y, Tokumaru S et al. (2006) A novel function of angiotensin II in skin wound healing. Induction of fibroblast and keratinocyte migration by angiotensin II via heparin-binding epidermal growth factor (EGF)-like growth factor-mediated EGF receptor transactivation. J Biol Chem 281: 13209-16
39. Yamamoto T (2010) Animal model of systemic sclerosis. J Dermatol 37: 26-41
40. Yang F, Chung ACK, Huang XR et al. (2009) Angiotensin II induces connective tissue growth factor and collagen I expression via transforming growth factor-beta-dependent and-independent Smad pathways: the role of Smad3. Hypertension 54: 877-84
41. Zhou L, Askew D, Wu C et al. (2007) Cutaneous gene expression by DNA microarray in murine sclerodermatous graft-versus-host disease, a model for human scleroderma. J Invest Dermatol 127: 281-92